CL7 1.5 mg (Rivastigmine tartrate 1.5 mg)
This pill with imprint "CL7 1.5 mg" is Yellow, Capsule-shape and has been identified as Rivastigmine tartrate 1.5 mg. It is supplied by Macleods Pharmaceuticals Limited.
Rivastigmine is used in the treatment of parkinson's disease; alzheimer's disease; lewy body dementia and belongs to the drug class cholinesterase inhibitors. There is no proven risk in humans during pregnancy. Rivastigmine 1.5 mg is not a controlled substance under the Controlled Substance Act (CSA).
Rivastigmine tartrate
- Imprint:
- CL7 1.5 mg
- Strength:
- 1.5 mg
- Color:
- Yellow
- Shape:
- Capsule-shape
- Availability:
- Prescription only
- Drug Class:
- Cholinesterase inhibitors
- Pregnancy Category:
- B - No proven risk in humans
- CSA Schedule:
- Not a controlled drug
- Labeler / Supplier:
- Macleods Pharmaceuticals Limited
- National Drug Code (NDC):
- 33342-0089
More about rivastigmine
- Side Effects
- During Pregnancy
- Dosage Information
- Drug Images
- Drug Interactions
- Support Group
- Pricing & Coupons
- 18 Reviews – Add your own review/rating
- Drug class: cholinesterase inhibitors
Consumer resources
- Rivastigmine
- Rivastigmine patch
- Rivastigmine solution
- Rivastigmine transdermal
- Rivastigmine (Advanced Reading)
- Rivastigmine Transdermal (Advanced Reading)
Other brands: Exelon
Professional resources
Related treatment guides
Disclaimer:
Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Copyright 2017 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.
